Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($9.23) earnings per share for the quarter, topping the consensus estimate of ($444.29) by $435.06, FiscalAI reports. The firm had revenue of $2.34 million for the quarter, compared to analyst estimates of $4.85 million.
Jaguar Animal Health Stock Performance
NASDAQ:JAGX opened at $0.42 on Monday. The firm has a market cap of $816,660.00, a price-to-earnings ratio of -0.00 and a beta of -0.09. Jaguar Animal Health has a 52 week low of $0.36 and a 52 week high of $1,039.50. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.40 and a current ratio of 0.69. The firm has a 50-day moving average price of $4.09 and a two-hundred day moving average price of $101.51.
Wall Street Analyst Weigh In
Several research firms recently commented on JAGX. Wall Street Zen raised Jaguar Animal Health to a “sell” rating in a research note on Saturday, October 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Thursday, October 15th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.
Read Our Latest Stock Report on JAGX
About Jaguar Animal Health
Jaguar Health, Inc., formerly Jaguar Animal Health, develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree. Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.
Read More
- Five stocks we like better than Jaguar Animal Health
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
